Clinical long-term outcomes of patient-reported outcomes in the prospective real-world Tofacitinib Response in Ulcerative Colitis (TOUR) registry: Tofacitinib Response in Ulcerative Colitis (TOUR).

Hans H HerfarthAnita AfzaliMonika FischerDavid HudesmanMaisa AbdallaRobert McCabeBenjamin L CohenRyan C UngaroWill HarlanJohn HansonGauree G KonijetiSteven PolyakTimothy RitterBruce SalzbergJennifer SeminerioEmily EnglishXian ZhangMillie D Long

Published in: Clinical and translational gastroenterology (2023)

Tofacitinib is an effective maintenance therapy in refractory UC patients. Dose reductions infrequently occurred during maintenance. Unmet needs in UC maintenance include improvement of urgency and psychosocial factors. (NCT03772145).

Keyphrases

ulcerative colitis
patient reported outcomes
end stage renal disease
rheumatoid arthritis
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
mesenchymal stem cells